s6y

Climb Bio, Inc.

Ticker
CLYM
CIK
1768446
Industry
Pharmaceutical Preparations
Formerly
Eliem Therapeutics, Inc.

Financials 23

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 23 financials filings

News 66

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 66 news filings

Ownership 143

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 3 Initial statement of beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 143 ownership filings

Prospectus 27

  1. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. S-3 Registration statement for specified transactions by certain issuers
  5. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. S-3 Registration statement for specified transactions by certain issuers

All 27 prospectus filings

Proxies 15

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEFM14A Definitive proxy statement relating to a merger, acquisition, or disposition
  10. PREM14A Preliminary proxy statement relating to a merger, acquisition, or disposition

All 15 proxies filings

Other 52

  1. SCHEDULE 13D/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. SCHEDULE 13G
  5. 144 Filing for proposed sale of securities under Rule 144
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G
  8. SCHEDULE 13D/A
  9. 144 Filing for proposed sale of securities under Rule 144
  10. EFFECT Notice of Effectiveness

All 52 other filings